Moura-Coelho Nuno, Cunha João Paulo, Dias-Santos Arnaldo, Dutra-Medeiros Marco, Papa-Vettorazzi Renato, Manero Felicidad, Güell José
Cornea and Refractive Surgery Unit, Instituto Microcirugía Ocular (IMO) Barcelona, Barcelona, Spain.
Ophthalmology, Faculdade de Ciências Médicas - Universidade Nova de Lisboa (NMS|FCM-UNL), Lisbon, Portugal.
Clin Ophthalmol. 2023 Mar 19;17:931-940. doi: 10.2147/OPTH.S401387. eCollection 2023.
To analyze the outcomes of Descemet's membrane endothelial keratoplasty (DMEK) for corneal endothelial failure secondary to phakic intraocular lens implantation (PIOL) at a reference center for corneal transplantation in Spain.
Retrospective, single-surgeon case series.
Single-center analysis of patients who underwent DMEK for PIOL-related corneal decompensation between July 2011 and July 2020 with at least 6 months of follow-up postoperatively. Primary outcome was final best-corrected visual acuity (BCVA, logMAR) compared to pre-DMEK BCVA. Secondary outcomes analyzed included post-DMEK refractive spherical equivalent, endothelial cell loss (%ECL), and graft failure.
Sixteen eyes (14 patients) underwent DMEK for PIOL-related corneal decompensation. Mean (SD) time to PIOL explantation was 9.3 (5.0) years, and median (P25-P75) time between PIOL explantation and DMEK surgery was 3 (2-4) months. Median pre-DMEK BCVA was 0.80 (1.08-0.60) logMAR. A statistically significant improvement in BCVA was observed 1 month after DMEK (p = 0.001), and median final BCVA was 0.15 (0.0-0.35) logMAR (p = 0.002). Mean %ECL was 55.6 (18.7) % at 2-year follow-up and 61.7 (11.7) % in eyes with over 4 years of follow-up. Two eyes required re-bubbling (12.5%), one of which ended in primary graft failure (6.2%) and one eye had late endothelial graft failure (LEGF) at 4-year follow-up (1/15 grafts, 6.7%).
In patients with PIOL-related corneal decompensation, DMEK leads to good and clinically significant refractive and visual outcomes in the medium-long term, with a good safety profile. Prospective studies are encouraged to ascertain whether these cases are at increased risk of accelerated endothelial cell loss and LEGF.
在西班牙一家角膜移植参考中心,分析Descemet膜内皮角膜移植术(DMEK)治疗有晶状体眼人工晶状体植入术(PIOL)后继发角膜内皮功能衰竭的效果。
回顾性、单术者病例系列研究。
对2011年7月至2020年7月间因PIOL相关角膜失代偿接受DMEK且术后至少随访6个月的患者进行单中心分析。主要结局是与DMEK术前最佳矫正视力(BCVA,logMAR)相比的最终最佳矫正视力。分析的次要结局包括DMEK术后等效球镜度、内皮细胞丢失率(%ECL)和植片失败情况。
16只眼(14例患者)因PIOL相关角膜失代偿接受了DMEK手术。PIOL取出的平均(标准差)时间为9.3(5.0)年,PIOL取出与DMEK手术之间的中位(第25-75百分位数)时间为3(2-4)个月。DMEK术前BCVA的中位数为0.80(1.08-0.60)logMAR。DMEK术后1个月观察到BCVA有统计学意义的改善(p = 0.001),最终BCVA的中位数为0.15(0.0-0.35)logMAR(p = 0.002)。2年随访时平均%ECL为55.6(18.7)%,随访超过4年的眼中为61.7(11.7)%。2只眼需要再次注气(12.5%),其中1只眼最终原发性植片失败(6.2%),1只眼在4年随访时发生晚期内皮植片失败(LEGF)(1/15例植片,6.7%)。
对于PIOL相关角膜失代偿患者,DMEK在中长期可带来良好且具有临床意义的屈光和视觉效果,安全性良好。鼓励开展前瞻性研究以确定这些病例是否存在内皮细胞加速丢失和LEGF风险增加的情况。